Capgemini SE (0HAZ)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 126.58 |
|---|---|
| 52-week range | 85.64 – 153.05 |
| Return, 1 month / 3 months | +18.6% / +42.5% |
| Return, 1 year / 3 years | +1.3% / −16.3% |
| Trend | Uptrend |
| RSI (14) | 76 |
| Volatility (1 year) | 39.7% |
| Worst drawdown (1 year) | -41.8% |
| Average daily value traded | 16.73M EUR |
| Dividend yield | 2.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Capgemini is a French information technology services and consulting firm based in Paris. It helps organisations design, build and run their technology systems, offering consulting, systems integration, application development and outsourcing services. Its clients come from many industries, including manufacturing, retail, financial services and the public sector, and it works with businesses and government bodies across Europe, North America and other regions. The company focuses on digital transformation and engineering work for large organisations.
The shares are listed on the London Exchange in UK under the code 0HAZ, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Capgemini SE (0HAZ) trades on the London Exchange in UK. It last closed at EUR 126.58 on 22 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 1,426 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 1.3% and over the last three months it rose 42.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 69 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 21.0% | ||
| From 52-week high | -16.9% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 42.5% | ||
| 6-month return | 22.1% | ||
| 12-month return, skipping the last month | -14.6% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.8% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 16.73M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 44 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.7% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.1% |
|---|---|
| 1 month | +18.6% |
| 3 months | +42.5% |
| 6 months | +22.1% |
| 1 year | +1.3% |
| 3 years | −16.3% |
| 5 years | −25.4% |
Signals
| 50-day / 200-day average | 109.79 / 104.64 |
|---|---|
| Golden / death cross (60 days) | Golden, 13 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.52 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jun 2026 | EUR 3.4000 |
| 20 May 2025 | EUR 3.4000 |
| 29 May 2024 | EUR 3.4000 |
| 30 May 2023 | EUR 3.2500 |
| 1 Jun 2022 | EUR 2.4000 |
| 2 Jun 2021 | EUR 1.9500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.